Trials / Completed
CompletedNCT02871440
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
A Two Comparator, Controlled Phase 3 Study of OM3 Tear Formulation Versus OPTIVE ADVANCED Unit Dose and OPTIVE Unit Dose Eye Drops in Patients With and Without Evaporative Dry Eye.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- The University of New South Wales · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Omega 3 (OM3) Tear is a new unit dose emulsion, containing flaxseed/castor oil, which is being developed by Allergan. It is desirable to understand the effect that this new emulsion has on tear film evaporation and tear lipid profile via interferometry, in patients with evaporative dry eye (EDE) and those without (non-EDE). It would also be valuable to evaluate the retention time of the lipid components of the new emulsion via tear collection and analysis in EDE and non-EDE patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omega 3 | |
| DRUG | Optive Advanced | |
| DRUG | Optive |
Timeline
- Start date
- 2016-09-19
- Primary completion
- 2017-09-18
- Completion
- 2017-09-18
- First posted
- 2016-08-18
- Last updated
- 2020-05-12
- Results posted
- 2020-05-12
Source: ClinicalTrials.gov record NCT02871440. Inclusion in this directory is not an endorsement.